FDA to require REMS of opioid-based drugs

Citing authority granted to the agency by the FDA Amendments Act of 2007 (FDAAA), FDA sent letters in early February to manufacturers of opioid painkillers, including Ortho McNeil Janssen, Purdue Pharma, Roxanne, King Pharma, Actavis, Xanodyne, Endo, Lavipharm Labs, Mylan […]

Read More

Canada Strives for Commercial-free Drug Messaging

 In what may be Canada’s largest experiment yet on academic detailing—the practice of healthcare professionals unaffiliated with drug companies updating doctors on available treatments—the Ontario Ministry of Health has issued a request for proposals to provide a province-wide pilot program. […]

Read More